Infinity Pharmaceuticals Inc.  

(Public, NASDAQ:INFI)   Watch this stock  
Find more results for INFI
8.74
+0.01 (0.11%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.65 - 9.03
52 week 8.42 - 18.25
Open 8.76
Vol / Avg. 414,253.00/565,053.00
Mkt cap 428.63M
P/E     -
Div/yield     -
EPS -1.39
Shares 49.04M
Beta 1.29
Inst. own 103%
Aug 11, 2015
Infinity Pharmaceuticals Inc at Wedbush PacGrow Healthcare Conference Add to calendar
Aug 6, 2015
Q2 2015 Infinity Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Aug 6, 2015
Q2 2015 Infinity Pharmaceuticals Inc Earnings Call - 8:30AM EDT - Add to calendar
Jul 28, 2015
Infinity Pharmaceuticals Inc at BMO Capital Markets Corporate Access Day
Jun 24, 2015
Infinity Pharmaceuticals Inc at JMP Securities Life Sciences Conference
Jun 15, 2015
Infinity Pharmaceuticals Inc Annual Shareholders Meeting
Jun 9, 2015
Infinity Pharmaceuticals Inc at William Blair Annual Growth Stock Conference
Jun 3, 2015
Infinity Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 18, 2015
Infinity Pharmaceuticals Inc at UBS Global Healthcare Conference
May 12, 2015
Infinity Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -2138.48% -10.56%
Operating margin -2122.74% -4.80%
EBITD margin - -3.73%
Return on average assets -117.54% -5.81%
Return on average equity -226.43% -8.48%
Employees 195 -
CDP Score - -

Address

784 Memorial Dr
CAMBRIDGE, MA 02139-4613
United States - Map
+1-617-4531000 (Phone)
+1-617-4531001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies. In addition to duvelisib, the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies), a worldwide investigation of duvelisib in blood cancers.

Officers and directors

Adelene Q. Perkins Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Lawrence E. Bloch M.D., J.D. Chief Financial Officer, Executive Vice President, Chief Business Officer
Age: 50
Bio & Compensation  - Reuters
Julian Adams Ph.D. President - Research & Development
Age: 60
Bio & Compensation  - Reuters
Winston K C Lam Executive Vice President, General Counsel
Bio & Compensation  - Reuters
Sujay Kango Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Vito J. Palombella Ph.D. Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
David A. Roth M.D. Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Norman C. Selby Lead Outside Independent Director
Age: 62
Bio & Compensation  - Reuters
Jose Baselga M.D., Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Jeffrey Berkowitz J.D. Independent Director
Age: 49
Bio & Compensation  - Reuters